Dose optimization of intravenous magnesium sulfate after acute stroke

被引:89
作者
Muir, KW [1 ]
Lees, KR [1 ]
机构
[1] Univ Glasgow, Western Infirm, Dept Med & Therapeut, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland
关键词
clinical trials; randomized controlled trials; neuroprotection; magnesium;
D O I
10.1161/01.STR.29.5.918
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Parenterally administered MgSO4 is neuroprotective in standard animal models of focal cerebral ischemia and in many other paradigms of brain injury. Previous small clinical trials in stroke patients have explored the safety and tolerability of different infusion regimens. This study was undertaken to optimize the regimen for a multicenter trial. Methods-Within 24 hours of the onset of clinically diagnosed stroke, patients were randomized to receive placebo or one of three intravenous MgSO4 infusions: a loading infusion of 8, 12, or 16 mmol, followed by 65 mmol over 24 hours. Cardiovascular parameters, serum magnesium concentrations, and blood glucose concentrations were determined. Outcome at 30 and 90 days was recorded. Results-Twenty-five patients were recruited and treated at a mean time of 20 hours after stroke. No tolerability problems were identified. No effects of magnesium on heart rate, blood pressure, or blood glucose were evident. Serum magnesium concentrations rose to target levels most rapidly in the highest loading infusion group and were maintained in all groups for at least 24 hours. Conclusions-MgSO4 infusions that rapidly elevate the serum magnesium concentration to potentially therapeutic levels are well tolerated and have no major hemodynamic effects in patients with acute stroke. The 16-mmol loading infusion achieved target serum concentrations most rapidly and has been chosen for further trials.
引用
收藏
页码:918 / 923
页数:6
相关论文
共 47 条
[41]   CEREBROSPINAL-FLUID LEVELS OF MAGNESIUM IN PATIENTS WITH PREECLAMPSIA AFTER TREATMENT WITH INTRAVENOUS MAGNESIUM-SULFATE - A PRELIMINARY-REPORT [J].
THURNAU, GR ;
KEMP, DB ;
JARVIS, A .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 157 (06) :1435-1438
[42]   MG2+ ADMINISTERED UP TO 24 HOURS FOLLOWING REPERFUSION PREVENTS ISCHEMIC DAMAGE OF THE CA1 NEURONS IN THE RAT HIPPOCAMPUS [J].
TSUDA, T ;
KOGURE, K ;
NISHIOKA, K ;
WATANABE, T .
NEUROSCIENCE, 1991, 44 (02) :335-341
[43]   MILD HYPOTHERMIA AND MG++ PROTECT AGAINST IRREVERSIBLE DAMAGE DURING CNS ISCHEMIA [J].
VACANTI, FX ;
AMES, A .
STROKE, 1984, 15 (04) :695-698
[44]   INTEROBSERVER AGREEMENT FOR THE ASSESSMENT OF HANDICAP IN STROKE PATIENTS [J].
VANSWIETEN, JC ;
KOUDSTAAL, PJ ;
VISSER, MC ;
SCHOUTEN, HJA ;
VANGIJN, J .
STROKE, 1988, 19 (05) :604-607
[45]  
WESTER PO, 1984, ACTA NEUROL SCAND, V70, P143
[46]   LONG-TERM OUTCOME AFTER INTRAVENOUS MAGNESIUM-SULFATE IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - THE 2ND LEICESTER INTRAVENOUS MAGNESIUM INTERVENTION TRIAL (LIMIT-2) [J].
WOODS, KL ;
FLETCHER, S .
LANCET, 1994, 343 (8901) :816-819
[47]   INTRAVENOUS MAGNESIUM-SULFATE IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE 2ND LEICESTER-INTRAVENOUS-MAGNESIUM-INTERVENTION-TRIAL (LIMIT-2) [J].
WOODS, KL ;
FLETCHER, S ;
ROFFE, C ;
HAIDER, Y .
LANCET, 1992, 339 (8809) :1553-1558